

1. [PricewaterhouseCoopers releases findings for transforming India into an innovation hub](#) – Pharmabiz.com

In line with the global industry's commitment to innovation in India, PricewaterhouseCoopers (PwC) had been commissioned to assess the innovation landscape of the Indian pharmaceutical industry and to suggest policy recommendations to help India move up the innovation value chain.

PwC released the findings from a study that captures the critical enablers for transforming India into an innovation hub on the occasion of Organisation of Pharmaceutical Producers of India (OPPI) hosted meet to honour a visiting global pharmaceutical delegation of Kenneth C. Frazier - chairman and CEO, Merck & Co, Inc., USA; and Hideshi Honda, president-Asia Region, Eisai Co Ltd. This event was in continuation of OPPI's golden jubilee celebration and aligned with the theme '50 Years: Healthy India, Innovative India.'

2. [Dr Reddy's FDA woes turn spotlight on compliance standards again](#) – Mint

It's tempting to wonder if the US drug regulator has the knives out for Indian pharmaceutical companies. After all, some of India's best-run companies—or so one thought—have fallen foul of its quality standards. Investors in these companies can't believe their eyes when they see that cash-rich companies with sound management have tripped over US Food and Drug Administration's (FDA) compliance standards.

That's why the Dr Reddy's Laboratories Ltd stock fell by as much as 14.7% on Friday, after it disclosed that three units have received warnings letters from the US FDA. Two API (active pharmaceutical ingredients, which are the main input used to make drugs) plants and one oncology formulation unit were affected.

3. [Cancer drug: HC seeks DCGI, Genentech reply on Reliance plea](#) – Business Standard

Delhi High Court today sought responses of Swiss pharma major Roche's subsidiary Genentech Inc and the Drug Controller General of India (DCGI) on a plea by Reliance Life Sciences challenging a single-judge order blocking the launch of its breast cancer drug. It listed the matter for further hearing on November 19.

4. [US envoy lauds joint efforts to make lives better](#) – Hindu Business Line

The US Ambassador to India Richard R Verma, speaking on 'Technology, Innovation and Societal Change' at the Indian Institute of Management Bangalore (IIMB) recently, said collaboration between Indians and Americans continues to save and change lives.

1. [PricewaterhouseCoopers releases findings for transforming India into an innovation hub](#) – Pharmabiz.com

2. [Dr Reddy's FDA woes turn spotlight on compliance standards again](#) – Mint

3. [Cancer drug: HC seeks DCGI, Genentech reply on Reliance plea](#) – Business Standard

4. [US envoy lauds joint efforts to make lives better](#) – Hindu Business Line

5. [Pfizer-Allergan deal would set up U.S. company for a split](#) – Reuters

6. [Insurance, public-private cooperation to accelerate healthcare industry growth: Experts](#) – Pharmabiz.com

7. [US drug regulator issues warning letter to Dr Reddy's three manufacturing facilities](#) – The Hindu Business Line

8. [Patents: The times, they are a-changin'](#) - Sinapseblog

9. [Why drug companies and Hollywood love the TPP](#) – Vox

Verma cited the joint research by the US Centers for Disease Control (CDC) and the National Institute for Mental Health and Neurosciences here to diagnose, test, and treat acute encephalitis syndrome. It causes hundreds of deaths around the world every year.

Referring to Indian innovators and their ties to the US, Verma said, "A discussion about the US and Indian innovation in Bengaluru would be incomplete without mentioning a few of the many visionaries from this part of India, who have brought our peoples closer and created thousands of Indian and American jobs in the process."

5. [Pfizer-Allergan deal would set up U.S. company for a split](#) – Reuters

A Pfizer Inc (PFE.N) merger with Ireland-based Allergan (AGN.N), in addition to providing tax benefits, would bolster the U.S. drugmaker's growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent.

Many Wall Street analysts believe Pfizer will decide to split late next year, after compiling three years of financial data treating its "established products" division, which sells generic medicines, and its "innovative" patent-protected medicines unit, as if they were separate companies.

Such a split would dramatically boost the company's profitability, because in-patents drugs command much higher prices that rise every year, as opposed to off-patent medicines, that become commoditized and their prices decline.

6. [Insurance, public-private cooperation to accelerate healthcare industry growth: Experts](#) – Pharmabiz.com

Wide healthcare insurance and public-private cooperation will help thwart all the problems concerning healthcare industry in India and accelerate its growth with a positive change, opined experts at the launch of ISB's healthcare management programme in New Delhi.

Expressing their views, they said insurance and public-private cooperation will be a major game changer and can act as a catalyst for the next big move in the healthcare sector. Though nascent in India, it can change the trajectory of coverage and cost of healthcare delivery. A marriage of healthcare provider and insurer can provide a seamless experience, opined Aniljit Singh, founder and non-executive chairman of Max India Group, while Dr. Prathap C Reddy, chairman of Apollo Hospitals said that while the government is doing a good job at the primary level, to improve the healthcare structure at the tertiary level, it needs to encourage more public-private co-operation.

7. [US drug regulator issues warning letter to Dr Reddy's three manufacturing facilities](#) – The Hindu Business Line

Pharma major Dr Reddy's Laboratories has received a warning letter from the US Food and Drug Administration (USFDA) on three of its plants.

The warning letter covered two facilities making active pharmaceutical ingredients (APIs) at Srikakulam (Andhra Pradesh) and Miryalaguda (Telangana), and a cancer products manufacturing facility at Duvvada (Visakhapatnam, AP), the company said on Friday, sending its stock price plummeting, eventually closing down 15 per cent on the BSE.

The US regulatory action follows earlier inspections of these sites in November 2014, January 2015 and February 2015, respectively.

8. [Patents: The times, they are a-changin'](#) - Sinapseblog

In a previous post, we informed our readers about the new, draft [Patent](#) rules that have been proposed by the Department of Industrial Policy and Promotion (DIPP), Government of India. The [preceding post by Ms. Nisha Kurian](#) presented an analysis of the proposed rules and sought to answer the question, if all measures to accelerate the [Patent](#) registration process had been explored by the DIPP through these rules.

While the proposed draft [Patent](#) rules are likely to become effective from the 26th of November, 2015 in India, the USPTO also seems to have introduced some new rules that have become effective since yesterday (5th November, 2015)! The USPTO had published a notice in the Federal Register earlier in October this year titled, [Change in Practice Regarding Correction of Foreign Priority Claims](#).

9. [Why drug companies and Hollywood love the TPP](#) – Vox

In 1998, the United States Congress granted a 20-year extension of copyright terms — from the life of the author plus 50 years to the life of the author plus 70 years. Economists like Nobel Laureate Milton Friedman were [incredulous](#), arguing that such long terms couldn't possibly increase the incentive to produce creative works.

The stakes are highest in pharmaceuticals, where industry groups are seeking new regulations to [limit competition from generic drugmakers](#), including extended patent terms and longer terms of exclusivity for a class of drugs called biologics. Critics say this will lead to higher prices, depriving millions of patients of access to lifesaving medicines. But defenders predict that drug companies will plow their profits into research and development, creating new drugs that will benefit everyone in the long run.